May 17-18 Big Data and the Evolution of Precision (Personalized) Medicine George Poste, Ph.D., Chief Scientist, Complex Adaptive Systems, Professor, Health Innovation, Arizona State University Next Steps in Cancer Immunotherapy Eric H. Rubin, M.D., Vice President and Therapeutic Area Head, Oncology Early Development, Merck Research Laboratories Use of Epigenetic Markers as Markers for Response in Clinical Trials Jeffrey Waring, Ph.D., Director, Pharmacogenetics and Pharmacogenomics, Abbvie Alpha E is the Target for Etrolizumab Treatment for Inflammatory Bowel Disease and May Predict Responses to Treatment Teresa Ramirez Montagut, Ph.D., Scientist, Development Sciences, Genentech Genomic Markers of Response to Anti-HER2 Therapies in Breast Cancer Christos Hatzis, Ph.D., Assistant Professor, Medicine, and Director, Bioinformatics, Breast Medical Oncology, Yale Comprehensive Cancer Center, Yale University School of Medicine Development of a Drug-Response Modeling Framework to Identify Cell Line-Derived Translational Biomarkers that Can Predict Treatment Outcome William Trepicchio, Ph.D., Senior Director, Translational Medicine, Takeda The Impact of Genomic Research during Drug Development Rebecca Blanchard, Ph.D., Executive Director, Genetics and Pharmacogenomics, Head of Clinical Pharmacogenomics and Operations, Merck Clinical Genomics of Solid and Liquid Biopsies in Patients with Solid Tumors Marc Ladanyi, M.D., Attending Pathologist and Chief, Molecular Diagnostics Service; Member, Human Oncology and Pathogenesis Program, Memorial Sloan-Kettering Cancer Center, New York Utility of Multi-Faceted Approaches for Biomarker Discovery Darrell R. Borger, Ph.D., Director, Biomarker Laboratory, Co-Director, Translational Research Laboratory, Massachusetts General Hospital Cancer Center Identification of Patient Subgroups through the Analysis of Blood RNA Profiling Data Christopher Roberts, Ph.D., Associate Director, Computational Biology, Biogen Idec Biomarkers for Patient Stratification and Precision Medicine: Cancer and Beyond Jaya Goyal, Ph.D., Senior Director, Precision Medicine, Value Based Medicine, Biogen Patient Selection Biomarkers – From the PDX Model Directly to the Clinic Ann Kapoun, Ph.D., Vice President, Translational Medicine, OncoMed Pharmaceuticals Biomarker Tests for Molecularly Targeted Therapies: Key to Unlocking Precision Medicine Debra G.B. Leonard, M.D., Ph.D., Chair and Professor, Department of Pathology and Laboratory Medicine, University of Vermont College of Medicine and Medical Center | 